« Top Headlines » Open DEMAT Account in 24 hrs  New Income Tax Act: ITR forms to be issued prior to FY28, says govt  GSTR-9C Explained: Turnover Limit, Due Date, Statement Format & How to Prepare It in Tally Prime (2025 Update)  Will Income Tax Department release new ITR forms by January 2026? Finance Ministry says this  The Government of India has strengthened MSME protection through strict payment rules, ensuring that Micro & Small Enterprises receive timely payments from buyers. Under the MSME Development Act (MSMED Act), 2006, buyers must make payments within:  ITR Refund Delays in India: Why They Happen & How to FastTrack Your Refund in 2025  ITR Refund Delay: From Bank Errors To Department Checks, 5 Big Reasons Your Refund Gets Stuck  Income Tax Slabs 2025: New Vs Old Regime; Which One Is Better For You For FY2025-26?  Seamless Integration: How Tally Prime Connects Businesses to the Digital Economy  Govt to notify new ITR forms, Income Tax Act 2025 rules by January 2026: CBDT chief  Digital Efficiency for MSMEs: The Tally Prime Advantage  5 Ways Tally Prime Reduces Cost and Boosts Productivity for Startups «  CBEC puts recoverable indirect tax arrears at Rs 4,484 cr... Too preachy for the fin min’s taste... » Tax sops for pharma R&D may be extended September, 05th 2006 In order to promote continuous research and development (R&D) activities in the pharmaceuticals sector, the Ministry of Chemicals and Fertilisers has sought approval from the Finance Ministry for extending the time limit of tax exemptions provided for such activities. "Time limit for tax exemption on research and development oriented companies has been under consideration by the Ministry of Chemicals and Fertilisers. A proposal has been sent to the Revenue Department for the extension and we are hopeful for a favourable move," the secretary in the Department of Chemicals and Petrochemicals, Ms Satwant Reddy told reporters here. She said the time limit on tax incentives provided to R&D oriented companies was supposed to expire on March 31, 2007 and the Ministry wants to extend it by another 10 years up to 2017, she said. Pharmaceutical companies that fall under the Government's gold standard criteria are entitled to get the tax benefit under the existing R&D policy. Speaking at a symposium on Dynamics of Innovation Leadership in Knowledge Based Industries, she said that the challenges for development of R& D activities are to improve physical infrastructure, HRD and systematic changes in the regulatory and IPR regime.